API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.clinicaltrialsarena.com/news/oncxerna-subject-navicixizumab-trial/
https://www.globenewswire.com/news-release/2022/09/08/2512403/0/en/OncXerna-Therapeutics-Doses-First-Patient-in-Phase-2-Trial-Evaluating-Navicixizumab-Alone-or-in-Combination-with-Chemotherapy-in-Patients-with-Select-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2021/10/23/2319430/0/en/OncXerna-Therapeutics-Announces-New-Biomarker-Data-from-Retrospective-Analysis-of-Results-from-Phase-1b-Ovarian-Cancer-Trial-of-Navicixizumab-Plus-Paclitaxel-at-the-ESGO-2021-Congr.html
https://www.prnewswire.com/news-releases/oncologie-announces-key-updates-and-planned-activities-for-its-clinical-programs-and-rna-based-biomarker-platform-301075224.html
https://www.globenewswire.com/news-release/2020/02/12/1983782/0/en/Mereo-BioPharma-Announces-Update-on-Distribution-Related-to-Contingent-Value-Rights-Following-Recent-Oncologie-Licensing-Agreement-for-Navicixizumab.html
https://www.contractpharma.com/contents/view_breaking-news/2020-01-14/oncologie-receives-exclusive-navicixizumab-license/
https://www.prnewswire.com/news-releases/mereo-biopharma-and-oncologie-enter-into-global-licensing-agreement-for-navicixizumab-300985393.html
https://finance.yahoo.com/news/mereo-biopharma-receives-fda-fast-120000197.html
https://www.globenewswire.com/news-release/2019/04/18/1806216/0/en/Mereo-BioPharma-Group-plc-Mereo-or-the-Company-or-the-Group-Merger-Update-Acquisition-of-OncoMed-Pharmaceuticals-Inc-OncoMed-Result-of-OncoMed-Stockholder-Meeting.html
https://www.globenewswire.com/news-release/2017/04/10/958277/0/en/OncoMed-Pharmaceuticals-Announces-Bayer-Terminates-its-Option-to-License-Vantictumab-or-Ipafricept.html